Last Patient, Last Visit in LAM561 Ph 2b/3 Trial for Newly Diagnosed GBM Patients Announced
“Reaching the ‘last patient, last visit’ is a milestone for Laminar Pharma and brings us one step closer to our goal of delivering a much-needed therapy to patients battling one the most aggressive forms of brain cancer”, said Dr. Pablo Escribà, CEO of Laminar Pharma. “We extend our deepest gratitude to the patients, their families, and the clinical investigators and healthcare personnel who have made this trial possible.”
Share:
More News
“With this financing, we are well positioned to complete IND-enabling studies and advance TAVST01 toward its planned IND submission, bringing us closer to delivering a scalable, readily available, and potentially transformative cell therapy for patients with solid tumors”, said Dr. Ivan Horak, Founder and Chief Executive Officer of Tikva Allocell.
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” said Vinita Gupta, Chief Executive Officer, Lupin. “The strength of these assets, combined with Kaveri’s seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of
Dr Jonathan Kwok, Co-Founder, President and Chief Medical Officer, Infinitopes, said, “Entering the clinic is a defining milestone for successful future medicines. For Infinitopes, VISTA represents the first clinical evaluation of our integrated approach that combines Precision Immunomics target discovery with proven viral vectors, to engineer precise, off-the-shelf therapies for